An Open-label, Single-dose, Randomized, Two-way, Two-period Crossover Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
Latest Information Update: 11 Dec 2025
At a glance
- Drugs Furosemide (Primary) ; Furosemide
- Indications Chronic heart failure; Oedema
- Focus Pharmacokinetics
- Sponsors SQ Innovation
Most Recent Events
- 11 Dec 2025 New trial record